Drugs for Cancer, Arthritis, and HIV on Medicare’s List for 2028 Price Cuts

Summary
The federal government has announced the next 15 medicines for which it will seek price reductions through Medicare’s negotiating power, including treatments for breast cancer, HIV, and rheumatoid arthritis. These cuts, allowed through the Inflation Reduction Act, will go into effect in 2028.

Access impact
The Centers for Medicare and Medicaid Services (CMS) designated these drugs for price negotiations in order to limit expenditures and ensure the system works for patients, not special interests. However, the industry group Pharmaceutical Research and Manufacturers of America argues that these negotiations are undermining future medical progress by discouraging investment in new drugs.

Top-3 domain lens
Cost-Effectiveness
According to analyst David Risinger, the price cuts will have minimal impact on most companies except for Gilead Sciences, whose drug Biktarvy could see a decrease in Medicare revenue by 8% in 2027.

Safety and Tolerability
The drugs selected for price negotiations have been deemed safe and tolerable for use in Medicare patients.

Evidence Quality and Robustness
The selection of these drugs for negotiations was based on their high usage and associated costs in the Medicare program, indicating their effectiveness and quality.

Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug #RegulatoryAgency

CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list

Source
source: https://www.biopharmadive.com/news/medicare-drug-price-2028-trulicity-biktarvy-verzenio-kisqali/810688/